Amylin Pharmaceuticals (AMLN) Could Be One To Watch On ImClone Bid

Watch Amylin Pharmaceuticals Inc. (Nasdaq: AMLN) on news that Bristol-Myers Squibb Co. (NYSE: BMY) offered to acquire ImClone (Nasdaq: IMCL) at a hefty premium of $60 per share.

Carl Icahn is a shareholder of AMLN and IMCL, in addition to Biogen Idec Inc. (Nasdaq: BIIB).

You May Also Be Interested In

• NVIDIA (NVDA) in talks to invest in data-center company Cloverleaf Infrastructure - WSJ
• Virtu Financial said to explore $3.5B sales of brokerage unit
• Mavis acquires Pep Boys from Icahn Enterprises for $700M